Department of Epidemiology, School of Public Health, Johns Hopkins University, Baltimore, MD 21205, United States.
Addict Behav. 2011 Jan-Feb;36(1-2):61-7. doi: 10.1016/j.addbeh.2010.08.022. Epub 2010 Sep 26.
Urban U.S. populations are burdened by intersecting epidemics of HIV infection, injection drug use, and cigarette smoking. Given the substantial morbidity attributable to tobacco in these populations, we characterized smoking behaviors, nicotine addiction, and tobacco exposure among HIV-infected and HIV-uninfected injection drug users (IDUs) in Baltimore, Maryland.
Smoking behaviors among participants in the ALIVE Study were assessed using interviewer-administered questionnaires. Smoking history and nicotine dependence (Fagerstrom Index scores) were compared by HIV and drug injecting status. Serum cotinine (a nicotine metabolite) was measured for a sample of participants by enzyme immunoassay.
Among 1052 participants (29.7% HIV-infected, 39.8% active injectors), 85.2% were current smokers and 9.3% were former smokers. Smoking prevalence, age at smoking initiation, and cumulative tobacco exposure were similar by HIV status. Median Fagerstrom scores of 4 for HIV-infected and HIV-uninfected smokers indicated moderate nicotine dependence. Daily cigarette consumption was identical by HIV status (median 10 cigarettes), although HIV-infected participants were less likely to smoke 1+ pack daily compared to HIV-uninfected participants (18.0% vs. 26.9%, p=0.001). Compared to former injectors, active injectors had higher smoking prevalence (90.5% vs. 81.7%, p=0.0001), greater daily cigarette consumption (30.7% vs. 19.6% smoked 1+ pack daily, p=0.0001), and slightly higher Fagerstrom scores (median 5 vs. 4). Cotinine levels paralleled self-reported cigarette consumption.
Tobacco use is extremely common among inner-city IDUs. Smoking behavior and nicotine dependence did not materially differ by HIV status but were associated with active drug injection. Cessation efforts should target the dual dependence of cigarettes and drugs experienced among this population.
美国城市人口正承受着艾滋病毒感染、注射吸毒和吸烟这三重流行疾病的困扰。鉴于这些人群中吸烟导致的大量发病率,我们对马里兰州巴尔的摩的艾滋病毒感染者和未感染者注射吸毒者(IDU)的吸烟行为、尼古丁成瘾和烟草暴露情况进行了研究。
通过访谈者管理的问卷评估了参与 ALIVE 研究的参与者的吸烟行为。根据 HIV 和药物注射状况比较了吸烟史和尼古丁依赖(Fagerstrom 指数评分)。通过酶免疫测定法测量了部分参与者的血清可替宁(尼古丁代谢物)。
在 1052 名参与者中(29.7% HIV 感染者,39.8% 为活跃的注射吸毒者),85.2%为当前吸烟者,9.3%为前吸烟者。HIV 状况相似,吸烟流行率、开始吸烟的年龄和累计烟草暴露量也相似。HIV 感染者和未感染者的 Fagerstrom 评分中位数为 4,表明中度尼古丁依赖。HIV 感染者和未感染者的每日吸烟量相同(中位数为 10 支),但与 HIV 未感染者相比,HIV 感染者较少每天吸 1 包以上(18.0% 对 26.9%,p=0.001)。与前注射吸毒者相比,活跃的注射吸毒者吸烟流行率更高(90.5%对 81.7%,p=0.0001),每日吸烟量更大(30.7%对 19.6%每天吸 1 包以上,p=0.0001),Fagerstrom 评分略高(中位数 5 对 4)。可替宁水平与自我报告的吸烟量相符。
在城市 IDU 中,吸烟非常普遍。吸烟行为和尼古丁依赖程度不因 HIV 状况而异,但与活跃的药物注射有关。应针对该人群同时依赖香烟和毒品的双重问题开展戒烟努力。